Lv3
220 积分 2022-06-01 加入
TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
7小时前
待确认
TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
7小时前
已完结
Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma
12天前
已完结
From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy
17天前
已完结
Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently
1个月前
已完结
Challenges facing CAR T-cell immunotherapy in multiple myeloma
1个月前
已完结
Tunneling CARs: Increasing CAR T-cell tumor infiltration through the overexpression of MMP-7 and Osteopontin-b
1个月前
已完结
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
1个月前
已完结
Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy
1个月前
已完结
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma
1个月前
已完结
皖公网安备34019202002308
